Elwy, F., Helwa, R., El Leithy, A., Shehab El-din, Z., Assem, M., Hassan, N. (2017). PIK3CA mutations in HER2-positive Breast Cancer Patients; Frequency and Clinicopathological Perspective in Egyptian Patients. Asian Pacific Journal of Cancer Prevention, 18(1), 57-64. doi: 10.22034/APJCP.2017.18.1.57
Fatma Elwy; Reham Helwa; Asmaa A. El Leithy; Zeinab Shehab El-din; Magda M. Assem; Nagwa H. A. Hassan. "PIK3CA mutations in HER2-positive Breast Cancer Patients; Frequency and Clinicopathological Perspective in Egyptian Patients". Asian Pacific Journal of Cancer Prevention, 18, 1, 2017, 57-64. doi: 10.22034/APJCP.2017.18.1.57
Elwy, F., Helwa, R., El Leithy, A., Shehab El-din, Z., Assem, M., Hassan, N. (2017). 'PIK3CA mutations in HER2-positive Breast Cancer Patients; Frequency and Clinicopathological Perspective in Egyptian Patients', Asian Pacific Journal of Cancer Prevention, 18(1), pp. 57-64. doi: 10.22034/APJCP.2017.18.1.57
Elwy, F., Helwa, R., El Leithy, A., Shehab El-din, Z., Assem, M., Hassan, N. PIK3CA mutations in HER2-positive Breast Cancer Patients; Frequency and Clinicopathological Perspective in Egyptian Patients. Asian Pacific Journal of Cancer Prevention, 2017; 18(1): 57-64. doi: 10.22034/APJCP.2017.18.1.57
PIK3CA mutations in HER2-positive Breast Cancer Patients; Frequency and Clinicopathological Perspective in Egyptian Patients
1Zoology Department, Faculty of Science, Ain Shams University, Cairo, Egypt
2Ain Shams University
3National Cancer Institute, Cairo University, Cairo, Egypt
4Department of Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
Receive Date: 15 September 2016,
Revise Date: 11 February 2017,
Accept Date: 11 February 2017
Abstract
Missense mutations in PIK3CA are common in breast cancers. They mostly involve exons 9 and 20 which encode kinase and helical domains of the protein and may result in its activation. PIK3CA activating mutations were previously shown to predict lower pathologic complete response (pCR) in HER2-positive breast cancer cases undergoing neoadjuvant human epidermal growth factor receptor 2-targeting therapy. Hence, the present work was conducted to estimate the mutation frequency in PIK3CA in 51 HER2-positive patients by direct sequencing. Our results showed 8 out of 51 (15.7%) to harbor PIK3CA mutations in either exon 9 or 20, or both. Three patients had mutations in both exons 9 and 20. Seven (13.7%) possess missense mutations in exon 20 which changed the amino acid sequence of the protein (H1047R, M1040I, and G1049G). Only four cases harbored mutations in exon 9, changing the codon sequences (E545K E545A, and R524K). Taking the clinicopathological data to account, the mutation frequency was greater in ductal than lobular carcinomas, in grade II rather than III and in lymph node positive lesions, with a higher HER2 score and which are ER/PR negative. However, none of the correlations proved statistically significant. In conclusion, to the best of our knowledge, the PIK3CA mutation frequency in this study is the first report regarding HER2-positive breast cancer patients in Egypt. Hereby, we highlight a moderate frequency which could be useful in the future as a predictive marker for anti-HER2 therapy.
Top